INmune Bio (NASDAQ: INMB) furnishes shareholder letter and press release

Rhea-AI Filing Summary

INmune Bio Inc. filed a current report to note that it issued a press release on January 27, 2026 announcing a shareholder letter. The letter is intended to provide shareholders with updates on the company’s prior and future operations.

The press release is included as Exhibit 99.1 and, along with the related disclosure, is being furnished under Regulation FD rather than filed. As a result, this information is not subject to certain liability provisions of the federal securities laws and will not be incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001711754 0001711754 2026-01-27 2026-01-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2026

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada		001-38793		47-5205835
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(561) 710-0512

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per shares		INMB		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 27, 2026, INmune Bio Inc. (the “Company”), issued a press release announcing the issuance of a shareholder letter providing updates to shareholders on prior and future operations.

A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01 and Item 9.01 (including Exhibit 99.1), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, amended (the “Securities Act”). In addition, the information in this Item 7.01 disclosure, including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1		Press Release dated January 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMUNE BIO INC.
Date: January 27, 2026	By:	/s/ David Moss
		David Moss
		Chief Executive Officer

2

FAQ

What did INMB disclose in its latest 8-K filing?

INmune Bio Inc. disclosed that it issued a press release announcing a shareholder letter that provides updates on prior and future operations, and furnished that press release as Exhibit 99.1.

What is included as Exhibit 99.1 in INMBs 8-K?

Exhibit 99.1 is a press release dated January 27, 2026, in which INmune Bio Inc. announces the issuance of a shareholder letter with operational updates.

Is the INMB shareholder letter information considered filed with the SEC?

No. The information in Item 7.01 and Item 9.01, including Exhibit 99.1, is being furnished, not filed, and is therefore not subject to certain liabilities under Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Will the INMB press release and shareholder letter be incorporated into other SEC filings?

The 8-K states that the information in Item 7.01, including Exhibit 99.1, will not be incorporated by reference into other Securities Act or Exchange Act filings unless expressly set forth by specific reference in such a filing.

What is the purpose of using Item 7.01 Regulation FD Disclosure for INMB?

Item 7.01 Regulation FD Disclosure is used so INmune Bio Inc. can furnish its press release and shareholder letter to ensure broad, fair disclosure of information to the market without treating it as formally filed.

Who signed the INMB 8-K related to the shareholder letter?

The 8-K was signed on behalf of INmune Bio Inc. by David Moss, who is identified as the Chief Executive Officer.